What is DOXIL®?
DOXIL® in combination with bortezomib is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. It is an intravenous (IV) prescription medication prescribed by your doctor. It is a type of chemotherapy drug known as an anthracycline.
If you have questions about bortezomib, you should ask your doctor or nurse.
Anthracyclines—one group of cancer drugs
Anthracyclines are a class of drugs that have been used for many years. Anthracyclines cause cancer cells to die by damaging the DNA, or the genetic makeup, of the cancer cells.
How is DOXIL® different?
DOXIL® is a specially coated form of doxorubicin that starts with the active agent, doxorubicin, and covers it with 2 layers of protective coating. This coating allows DOXIL® to evade detection and destruction by the immune system, which increases the time the drug is in the body. As a result, DOXIL® has more time to reach the tumor tissue, where the medication is released. However, DOXIL® may also affect normal tissue.
If you have more questions about how DOXIL® is different from other anthracyclines, ask your doctor or nurse.
Who should not receive DOXIL®?
You should not receive DOXIL® if you have had a severe reaction to doxorubicin HCl or to the other components of DOXIL®. Be sure to discuss any allergies you may have with your doctor or nurse. Women who are pregnant, planning on becoming pregnant, or nursing should not receive DOXIL®. If you have questions about whether or not you should receive DOXIL®, be sure to ask your doctor or nurse.